Elevara Medicines
Elevara Raises $70M to Advance Novel Rheumatoid Arthritis Treatment Targeting Synovial Fibroblasts
Elevara Medicines; Series A financing; rheumatoid arthritis; ELV001; CDK4/6 inhibitor; synovial fibroblasts; Teijin Pharma; clinical trial; chronic inflammatory diseases; Forbion; Sofinnova Partners